A
Arcus Biosciences, Inc. (RCUS)
NYQ – Real vaqt narxi. Valyuta: USD
24.90
+0.04 (0.16%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NYQ – Real vaqt narxi. Valyuta: USD
24.90
+0.04 (0.16%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Arcus Biosciences, Inc. klinik bosqichdagi biofarmatsevtika kompaniyasi bo'lib, Qo'shma Shtatlarda saratonni davolash terapiyalarini ishlab chiqadi va tijoratlashtiradi. Kompaniyaning rivojlanish mahsulotlari portfeliga buyrak saratonini davolash uchun HIF-2α inhibitörü bo'lgan Casdatifan; o'pka va oshqozon-ichak saratonlari uchun II va III bosqich klinik sinovlarida bo'lgan anti-TIGIT antikori bo'lgan Domvanalimab; va anti-PD-1 antikori bo'lgan Zimberelimab kiradi. Kompaniya, shuningdek, o'pka va oshqozon osti bezi saratonlari uchun III va I/Ib bosqichli klinik sinovlarda bo'lgan ATP-adenozin yo'lidagi CD73 fermentini nishonga oluvchi kichik molekulali ingibitor Quemliclustatni ishlab chiqadi. Bundan tashqari, kompaniya oshqozon-ichak saratonini davolash uchun I/Ib bosqichli klinik tadqiqotda bo'lgan CD39 antikori AB598 va o'pka saratonini davolash uchun Ib bosqichli klinik sinovda bo'lgan AXL ingibitori AB801ni ishlab chiqadi. Kompaniya AstraZeneca bilan III bosqichli PACIFIC-8 sinovida domvanalimab va durvalumabni III bosqichli NSCLCda baholash uchun va BVF Partners L.P. bilan IO-naïve bemorlarda ccRCC va BVFda kasdatifan va volrustomigni baholash uchun I/Ib bosqichli tadqiqotda hamda yallig'lanish kasalliklarini davolash uchun birikmalarni kashf qilish va rivojlantirishni qo'llab-quvvatlash bo'yicha klinik hamkorlikka ega. Arcus Biosciences, Inc. 2015 yilda ro'yxatga olingan va Xeyuard, Kaliforniya shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jonathan Yingling Ph.D. | Chief Scientific Officer |
| Dr. Juan Carlos Jaen Ph.D. | Co- Founder & President |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Richard A. Markus M.D., Ph.D. | Chief Medical Officer |
| Dr. Terry J. Rosen Ph.D. | Co-Founder, Chairman & CEO |
| Mr. Alexander Azoy CPA | Chief Accounting Officer |
| Mr. Robert C. Goeltz II | Principal Financial Officer & CFO |
| Ms. Carolyn C. Tang J.D. | General Counsel & Corporate Secretary |
| Ms. Jennifer A. Jarrett M.B.A. | Advisor |
| Pia Eaves | Vice President of Investor Relations & Strategy |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-05 | 8-K | rcus-20260505.htm |
| 2026-05-05 | 10-Q | rcus-20260331.htm |
| 2026-04-21 | DEFA14A | arcusfy2026proxynotice.htm |
| 2026-04-20 | 8-K | rcus-20260420.htm |
| 2026-03-23 | 8-K | rcus-20260317.htm |
| 2026-02-25 | 8-K | rcus-20260225.htm |
| 2026-02-25 | 10-K | rcus-20251231.htm |
| 2025-12-18 | 8-K | rcus-20251218.htm |
| 2025-12-12 | 8-K | rcus-20251212.htm |
| 2025-11-03 | 8-K | d912891d8k.htm |